^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Radspherin
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Oncoinvent
Drug class:
Ionizing radiation emitter
Related drugs:
28d
Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (clinicaltrials.gov)
P1/2, N=67, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
Enrollment closed
|
Radspherin
28d
Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (clinicaltrials.gov)
P1, N=49, Active, not recruiting, Oncoinvent AS | Recruiting --> Active, not recruiting
Enrollment closed
|
Radspherin
9ms
Effect of Intraperitoneal Radium-Labelled Microparticles on Compartmentalized Inflammation After Cytoreductive Surgery and Hypertherm Intraperitoneal Chemotherapy. (PubMed, Technol Cancer Res Treat)
Our study showed a predominately local rather than systemic inflammatory response to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Radspherin® had overall modest impact on the inflammation.
Journal • Surgery
|
IFNG (Interferon, gamma) • CCL4 (Chemokine (C-C motif) ligand 4) • IL1R1 (Interleukin 1 receptor, type I)
|
Radspherin
Share via
